Diana Brainard

DIANA BRAINARD is vice president of clinical research, liver diseases at Gilead Sciences, Inc. Over the last seven years she has overseen the clinical development of four new medicines that have revolutionized the treatment of chronic hepatitis c virus infection, including Sovaldi which won the Prix Galien in 2014 for best biotechnology product. Brainard trained as an infectious diseases physician at Massachusetts General Hospital and was on faculty at Harvard Medical School where she conducted NIH-funded research on HIV immunology prior to joining the pharmaceutical industry in 2007. Since then, her passion for advancing therapies for life threatening diseases and for building authentic and mutually inspirational relationships/teams in the workplace have guided her journey in the world of drug development. Brainard earned a BA in comparative literature at Brown University and an MD at Tulane University School of Medicine. @gilead

Subscribe to our eNewsletter